Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival

Shahab Uddin, Azhar R. Hussain, Abdul K. Siraj, Pulicat S. Manogaran, Naif A. Al-Jomah, Azadali Moorji, Valerie Atizado, Fouad Al-Dayel, Asim Belgaumi, Hassan El-Solh, Adnan Ezzat, Prashant Bavi, Khawla S. Al-Kuraya

Research output: Contribution to journalArticlepeer-review

238 Citations (Scopus)

Abstract

Phosphatidylinositol 3′-kinase (PI3K) is a key player in cell-growth signaling in a number of lymphoid malignancies, but its role in diffuse large B-cell lymphoma (DLBCL) has not been fully elucidated. Therefore, we investigated the role of the PI3K/AKT pathway in a panel of 5 DLBCL cell lines and 100 clinical samples. Inhibition of PI3K by a specific inhibitor, LY294002, induced apoptosis in SUDHL4, SUDHL5, and SUDHL10 (LY-sensitive) cells, whereas SUDHL8 and OCI-LY19 (LY-resistant) cells were refractory to LY294002-induced apoptosis. AKT was phosphorylated in 5 of 5 DLBCL cell lines and inhibition of PI3K caused dephosphorylation/inactivation of constitutively active AKT, FOXO transcription factor, and GSK3 in LY-sensitive cell lines. In addition, there was a decrease in the expression level of inhibitory apoptotic protein, XIAP, in the DLBCL cell lines sensitive to LY294002 after treatment. However, no effect was observed in XIAP protein levels in the resistant DLBCL cell lines following LY294002 treatment. Finally, using immunohistochemistry, p-AKT was detected in 52% of DLBCL tumors tested. Furthermore, in univariate analysis, high p-AKT expression was associated with short survival. In multivariate analysis, this correlation was no longer significant. Altogether, these results suggest that the PI3K/AKT pathway may be a potential target for therapeutic intervention in DLBCL.

Original languageEnglish
Pages (from-to)4178-4186
Number of pages9
JournalBlood
Volume108
Issue number13
DOIs
Publication statusPublished - 15 Dec 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival'. Together they form a unique fingerprint.

Cite this